Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
In conclusion, we demonstrated that ARQ 092 blocks AKT phosphorylation in vitro and in vivo. In the HCC-rat model, ARQ 092 was well tolerated, showed antifibrotic effect, and had stronger antitumor effect than sorafenib. Our results confirm the importance of targeting AKT in HCC. Mol Cancer Ther; 16(10); 2157–65. ©2017 AACR.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Roth, G. S., Macek Jilkova, Z., Zeybek Kuyucu, A., Kurma, K., Ahmad Pour, S. T., Abbadessa, G., Yu, Y., Busser, B., Marche, P. N., Leroy, V., Decaens, T. Tags: Small Molecule Therapeutics Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Nutrition | Urology & Nephrology